FDA Investigators Explain How to Avoid Enforcement Actions
This article was originally published in The Gold Sheet
Executive Summary
Pharmaceutical manufacturers need to take a more proactive approach to GMP compliance to ward off potential enforcement actions such as Form 483 reports, warning letters and withhold recommendations, FDA investigators told a recent conference. The key: No surprises.